sglt2 inhibitors vs glp-1 agonists Frontiers Cardiovascular and mortality outcomes with

You end up guessing

[DOI] [PubMed] [Google Scholar] 22.de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cam J

Soliman, A., Yasin, M., El-Awwa, A., Osman, M

Myocardial remodelling characterized by fibrosis and hypertrophy, impaired microcirculation, abnormal protein function caused by advanced glycation end products, changes in myocardial metabolism and abnormal mitochondrial function have been noted as associated factors of diabetic cardiomyopathy [14]

PMID: 21356520

Thank you to everyone at the IVBOOST I can highly recommend this place if you want to elevate your health and feel safe, Comfortable and well looked after